Feline Cutaneous Hemangiosarcoma: A Retrospective Study of 18 Cases (1998–2003)

2005 ◽  
Vol 41 (2) ◽  
pp. 110-116 ◽  
Author(s):  
Kevin P. McAbee ◽  
Lori L. Ludwig ◽  
Philip J. Bergman ◽  
Shelly J. Newman
Keyword(s):  
Surgical Excision ◽  
Tumor Location ◽  
Survival Times ◽  
Disease Free Interval ◽  
Free Interval ◽  
Complete Surgical Excision ◽  
Treatment Type ◽  
Long Term Prognosis ◽  
Disease Free

Cutaneous hemangiosarcoma (HSA) has been infrequently reported in dogs and cats. Medical records of 18 cats diagnosed with cutaneous HSA were reviewed. Age at the time of diagnosis, breed, sex, tumor location, tumor size, treatment type, survival time, disease-free interval, and cause of death were evaluated. Aggressive surgical excision of the tumor was attempted in 10 cats. A complete surgical excision was achieved in five of the 10 cats. Median survival times were statistically longer in cats that underwent surgery versus cats that did not. Cats with cutaneous HSA treated with aggressive surgical excision of their tumors may have a good long-term prognosis.

Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.

1991 ◽  
Vol 9 (7) ◽  
pp. 1151-1156 ◽  
Author(s):  
A Lipton ◽  
H A Harvey ◽  
C M Balch ◽  
C E Antle ◽  
R Heckard ◽  
...  
Keyword(s):  
Medical Center ◽  
Stage Ii ◽  
P Value ◽  
Survival Times ◽  
Bacille Calmette Guerin ◽  
Disease Free Interval ◽  
Adjuvant Immunotherapy ◽  
Corynebacterium Parvum ◽  
Free Interval ◽  
Disease Free

Two separate studies have been reported comparing Corynebacterium parvum and bacille Calmette-Guérin (BCG) as adjuvant immunotherapy for stage II melanoma patients (The Milton S. Hershey Medical Center, 48 patients; Southeastern Cancer Study Group [SECSG], 162 patients). As the criteria for patient selection and drugs used were similar, we have pooled the data to analyze the effects of these two treatments. Both studies used BCG (Tice, Chicago, IL) 3 x 10(8) live organisms per treatment by Tine technique and C parvum (Burroughs-Wellcome, Triangle Park, NC) subcutaneous at a dose of 4 mg/m2 (SECSG) or 5 micrograms/m2 (Hershey) per treatment. The only difference in these studies was the frequency of immunization, with patients in Hershey receiving 22 doses and the SECSG patients receiving 55 doses during the 2-year period of treatment. Kaplan-Meier life-table analysis for the 210 patients shows a prolonged disease-free interval for patients treated with C parvum (P = .02, two-sided Mantel procedure). In similar fashion, patients treated with C parvum had an improved survival rate (from all causes) when compared with BCG-treated patients (P = .012). An analysis of the results for the 170 patients for which the number of positive nodes was available was performed using Cox's model, with nodes as a stratification variable and with covariates of place, treatment, age, and sex. In this analysis, an observed benefit for C parvum on the disease-free interval had a P value of .37 while the benefit of C parvum on the survival times (from all causes) had a P value of .04. When the same analysis was performed using only patients aged younger than 60 years, the observed benefit of C parvum on disease-free interval had a P value of .08 and the benefit of C parvum on survival times (from all causes) had a P value of .008.

Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up

1985 ◽  
Vol 6 (2) ◽  
pp. 123-130 ◽  
Author(s):  
J. M. M. Raemaekers ◽  
L. V. A. M. Beex ◽  
A. J. M. Koenders ◽  
G. F. F. M. Pieters ◽  
A. G. H. Smals ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Tumor Tissue ◽  
Disease Free Interval ◽  
Free Interval ◽  
Estrogen Receptor Activity ◽  
Long Term Follow Up ◽  
Disease Free

Feline cutaneous squamous cell carcinoma of the nasal planum and the pinnae: 61 cases

1997 ◽  
Vol 33 (4) ◽  
pp. 329-332 ◽  
Author(s):  
SE Lana ◽  
GK Ogilvie ◽  
SJ Withrow ◽  
RC Straw ◽  
KS Rogers
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Medical Records ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Disease Free Interval ◽  
Free Interval ◽  
Treatment Type ◽  
Methods Of Treatment ◽  
Disease Free

Cutaneous squamous cell carcinoma is a common tumor in cats and frequently occurs on the nasal planum and the pinnae. The medical records of 61 cats were reviewed for this retrospective study. Typical presentation was an older (median age, 12 years) cat with an erythematous, crusty, and erosive lesion. Methods of treatment included surgery, radiation, and cryotherapy. Disease-free interval and survival time were calculated for each case and grouped according to lesion location and treatment type. All treatments were found to be effective, with surgery resulting in the longest disease-free interval (median, 594 days).

Primary rib tumors in 54 dogs

1995 ◽  
Vol 31 (1) ◽  
pp. 65-69 ◽  
Author(s):  
N Pirkey-Ehrhart ◽  
SJ Withrow ◽  
RC Straw ◽  
EJ Ehrhart ◽  
RL Page ◽  
...  
Keyword(s):  
Median Survival ◽  
Survival Times ◽  
En Bloc ◽  
Primary Tumors ◽  
Disease Free Interval ◽  
Free Interval ◽  
Resected Tumor ◽  
En Bloc Excision ◽  
Bloc Excision ◽  
Disease Free

Fifty-four dogs with primary tumors of the rib were evaluated. Thirty-four dogs had osteosarcomas, 15 dogs had chondrosarcomas, three dogs had hemangiosarcomas, and two dogs had fibrosarcomas. Forty-nine dogs had en bloc excision. Within the osteosarcoma group, nine animals received postoperative adjuvant chemotherapy. These animals had significantly longer median disease-free intervals (225 days) and median survival times (240 days) than dogs with osteosarcoma treated by surgery alone (median disease-free interval, 60 days; median survival, 90 days). Chondrosarcoma had a better prognosis (median disease-free interval, 1,080 days; median survival, 1,080 days) than osteosarcoma, hemangiosarcoma, or fibrosarcoma of the rib. Age, weight, sex, number of ribs resected, tumor volume, and total cisplatin dose did not influence survival nor disease-free interval.

A Review of 18 Cases of Feline Colonic Adenocarcinoma Treated with Subtotal Colectomies and Adjuvant Carboplatin

2012 ◽  
Vol 48 (6) ◽  
pp. 399-404 ◽  
Author(s):  
Theresa A. Arteaga ◽  
JoAnne McKnight ◽  
Philip J. Bergman
Keyword(s):  
Prognostic Factors ◽  
Median Survival ◽  
Subtotal Colectomy ◽  
Surgical Excision ◽  
Metastatic Tumor ◽  
Colonic Adenocarcinoma ◽  
Disease Free Interval ◽  
Free Interval ◽  
Carboplatin Dose ◽  
Disease Free

Feline colonic adenocarcinoma is a locally invasive, highly metastatic tumor that is most often treated with wide surgical excision (subtotal colectomy) and systemic chemotherapy either with or without nonsteroidal anti-inflammatory medications. In this retrospective study, the outcome of subtotal colectomy and adjuvant carboplatin in 18 client-owned cats is described. The median carboplatin dose was 200 mg/m2 (range, 200–254 mg/m2) q 4 wk with a median of five doses/cat (range was two to seven doses/cat). Limited toxicities were noted. Positive prognostic factors for the disease-free interval included cats that had weight loss as a presenting sign (P < 0.036) and negative prognostic factors for median survival included nodal and distant metastasis (178 versus 328 days and 200 versus 340 days, respectively). The median disease-free interval was 251 days (range, 37–528 days) and the median survival time was 269 days (range, 40–533 days). Subtotal colectomy and adjuvant carboplatin is a safe and potentially effective treatment for cats with colonic adenocarcinoma.

Recurrent immature teratoma of the ovary with long-term disease-free interval

2014 ◽  
Vol 40 (5) ◽  
pp. 1455-1458 ◽  
Author(s):  
Harunobu Matsumoto ◽  
Chiharu Mizoguchi ◽  
Masakazu Nishida ◽  
Shimpei Sato ◽  
Kaei Nasu ◽  
...  
Keyword(s):  
Immature Teratoma ◽  
Disease Free Interval ◽  
Free Interval ◽  
Disease Free

Metastatic Renal Cell Carcinoma Mimicking a Meningioma

Neurosurgery ◽  
1983 ◽  
Vol 13 (4) ◽  
pp. 430-434 ◽  
Author(s):  
K. Killebrew ◽  
M. Krigman ◽  
M. S. Mahaley ◽  
J. H. Scatliff
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Primary Tumor ◽  
Renal Cell ◽  
Term Survival ◽  
Disease Free Interval ◽  
Free Interval ◽  
Solitary Metastases ◽  
Disease Free

Abstract We report a patient with renal cell carcinoma metastatic to the left trigone, which mimicked an intraventricular meningioma. The metastasis was recognized 13 years after removal of the primary tumor, a longer disease-free interval than any previously reported cases with brain metastases of renal cell carcinoma. The patient is now free of disease 4 years after resection and 17 years after the discovery of the primary tumor. Metastatic disease should be considered in all patients with prior resection of renal cell carcinoma who experience the onset of neurological disease, even after a prolonged disease-free interval. Long term survival is observed after the resection of solitary metastases, particularly if these appear after a prolonged disease-free interval.

scholarly journals Lymph node micrometastases detected by carcinoembryonic antigen mRNA affect long-term survival and disease-free interval in early-stage lung cancer patients

2012 ◽  
Vol 4 (5) ◽  
pp. 1140-1144 ◽  
Author(s):  
MARIO NOSOTTI ◽  
ALESSANDRO PALLESCHI ◽  
LORENZO ROSSO ◽  
DAVIDE TOSI ◽  
LUIGI SANTAMBROGIO ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
Early Stage Lung Cancer ◽  
Term Survival ◽  
Disease Free Interval ◽  
Lung Cancer Patients ◽  
Free Interval ◽  
Disease Free ◽  
Stage Lung Cancer

Non-surgical Treatments for Lung Metastases in Patients with soft Tissue Sarcoma: Stereotactic Body Radiation Therapy (SBRT) and Radiofrequency Ablation (RFA)

2020 ◽  
Vol 16 ◽  
Author(s):  
Cecilia Tetta ◽  
Maria Carpenzano ◽  
Areej Tawfiq J Algargoush ◽  
Marwah Algargoosh ◽  
Francesco Londero ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Stereotactic Body Radiation Therapy ◽  
Lung Metastases ◽  
Disease Free Interval ◽  
Stereotactic Body Radiation ◽  
Free Interval ◽  
Disease Free

Background: Radio-frequency ablation (RFA) and Stereotactic Body Radiation Therapy (SBRT) are two emerging therapies for lung metastases. Introduction: We performed a literature review to evaluate outcomes and complications of these procedures in patients with lung metastases from soft tissue sarcoma (STS). Method: After selection, seven studies were included for each treatment encompassing a total of 424 patients: 218 in the SBRT group and 206 in the RFA group. Results: The mean age ranged from 47.9 to 64 years in the SBRT group and from 48 to 62.7 years in the RFA group. The most common histologic subtype was, in both groups, leiomyosarcoma. : In the SBRT group, median overall survival ranged from 25.2 to 69 months and median disease-free interval from 8.4 to 45 months. Two out of seven studies reported G3 and one G3 toxicity, respectively. In RFA patients, overall survival ranged from 15 to 50 months. The most frequent complication was pneumothorax. : Local control showed high percentage for both procedures. Conclusion: SBRT is recommended in patients unsuitable to surgery, in synchronous bilateral pulmonary metastases, in case of deep lesions and in patients receiving high-risk systemic therapies. RFA is indicated in case of a long disease-free interval, in oligometastatic disease, when only the lung is involved, in small size lesions far from large vessels. : Further large randomized studies are necessary to establish whether these treatments may also represent a reliable alternative to surgery.

Sign in / Sign up

Export Citation Format

Share Document